Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790204 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of PEITC on Oral Cells With Mutant p53
A Phase 1 study of Oral Cancer, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT01790204: Completed Phase 1 study of Oral Cancer, sponsored by Georgetown University.
NCT01790204 is a Phase 1 study of Oral Cancer that has completed, run by Georgetown University. The registered enrollment target is 55 participants, below the 210-participant average among 17 other Oral Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01790204, a Phase 1 study of Oral Cancer, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this clinical trial is to examine the effects of phenethyl isothiocyanate (PEITC), a compound derived from cruciferous vegetables, on oral cells with mutant p53. The p53 protein's normal (wild-type) function within cells is to act as a tumor suppressor, or anti-cancer protein. When mutated, the p53 protein not only no longer executes the functions of a tumor suppressor, and it can gain functions as a pro-cancer protein.22 The proposed clinical trial will utilize oral cells collected from subjects who are heavy smokers. Since the subjects are regularly exposed to mutagenic chemicals it is the thought that their oral cells will contain measurable levels of mutant p53. The participants will consume watercress juice, which is rich in PEITC (See Figure 1). Previous studies in the laboratory showed PEITC selectively depletes mutant p53, and not wild type p53, in cell culture. Our hypothesis is that the ITC in the watercress juice will lead to the depletion of mutant p53 within the oral cells. This depletion could lead to a possible clinical application of this compound, such as chemopreventives or oncologic treatments of individuals with oral cancers.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Watercress Juice
Study Locations (1)
District of Columbia
- Georgetown Clinical Research Unit - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
What the finished NCT01790204 record still lists
NCT01790204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 210-participant average among 17 other Oral Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Oral Cancer appearing as the primary indexed condition, and to 1 intervention - of which Watercress Juice is the first listed.
NCT01790204 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01790204 about?
NCT01790204 is a clinical study titled "A Study of the Effects of PEITC on Oral Cells With Mutant p53". The aim of this clinical trial is to examine the effects of phenethyl isothiocyanate (PEITC), a compound derived from cruciferous vegetables, on oral cells with mutant p53. The p53 protein's normal (wild-type) function within cells is to act as a tumor suppressor, or anti-cancer protein. When mutate...
What is the current status of trial NCT01790204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-02. Estimated completion is 2014-04.
What conditions does trial NCT01790204 study?
This clinical trial studies the following conditions: Oral Cancer.
What interventions are being tested in trial NCT01790204?
The interventions under investigation include: Watercress Juice (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01790204?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01790204 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oral Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01790204's enrollment target sits among peer trials
55 9th of 17 higher than 9 of 17 other Oral Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oral Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Use of Functional Confections in Promoting Oral Health
ACTIVE NOT RECRUITING · Phase 1
-
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
RECRUITING · NA
-
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
RECRUITING
-
Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain
RECRUITING · NA
-
Clinical and Molecular Features of Oral Premalignancy and Oral Cancer
RECRUITING
-
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia